KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.
性状
Solid
体外研究(In Vitro)
KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) acetate increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner.KY-02327 (1-10 μM) acetate increases the mRNA levels of osteoblast differentiation markers collagen 1a ( Col1a ) and osteocalcin ( OCN ). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) acetate successfully rescues bone loss in the ovariectomized (OVX) mouse model. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献
[1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387.
溶解度数据
In Vitro: DMSO : 50 mg/mL (115.34 mM; ultrasonic and warming and heat to 60°C)配制储备液